findmyKOL

Mark Latina, MD

Enriched profile

Ophthalmologist, Glaucoma and Comprehensive Ophthalmology · Specialty Eye Consultants

ORCIDNone on fileNPI
Region🇺🇸 Reading, MA · Northeast · United StatesSpecialtyOphthalmologyFocusGlaucoma
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceverified 2026Payments2021–2025NIH funding1987–1991Why? →

Mark Latina is Ophthalmologist, Glaucoma and Comprehensive Ophthalmology at Specialty Eye Consultants. ClinicalTrials.gov lists 2 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 2 Sept 2026

Mark A. Latina, MD, is Ophthalmologist, Glaucoma and Comprehensive Ophthalmology at Specialty Eye Consultants, LLC (practice brand: Advanced Glaucoma Specialists), Reading, MA -- MGB Affiliated Provider. The public record shows 93 publications with 3,216 citations (h-index 26), centered on Glaucoma. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 30 companies, 1 NIH-funded awards (1987–1991).

  • Top research focus: Glaucoma
  • 2 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 30 companies

Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Glaucoma2 trialsComa2 trialsHypertension1 trialOcular Hypertension1 trial

Research focus

OpenAlex concept fingerprint
Glaucoma

Drugs & molecules

across trials, industry payments and publications
Durystageneric · BimatoprostClinical trialsIndustry payments284PublicationsRocklatangeneric · Latanoprost / netarsudilClinical trialsIndustry payments117PublicationsRhopressageneric · NetarsudilClinical trialsIndustry payments67Publications

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trialsIndustry payments276Alcon Vision LLCClinical trialsIndustry payments127Sight Sciences, Inc.Clinical trialsIndustry payments77

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
26h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials
30companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 1987–1991

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 2 Sept 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 2 Sept 2026

30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    77.2%
    Prostaglandin Analog25.5%
    Bimatoprost61%Latanoprost23%Lumigan11%Tafluprost3%Travoprost2%Iyuzeh1%
    Part D + Part B<11 patients
    Carbonic Anhydrase Inhibitor20.8%
    Dorzolamide-Timolol43%Brinzolamide21%Dorzolamide Hcl16%Acetazolamide7%Simbrinza4%Acetazolamide Er4%Azopt4%Cosopt Pf2%
    Part D<11 patients
  • Cardiovascular

    11.8%
    Beta blocker11.8%
    Timolol Maleate90%Betaxolol Hcl7%Betoptic S4%
    Part D<11 patients
  • Nervous system

    4.5%
    Cholinergic Receptor Agonist4.5%
    Pilocarpine Hcl100%
    Part D91 patients
5 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 2 Sept 2026

1 NIH research award on record, funded 19871991 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 2 Sept 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/mark-latina-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/marklatina

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Mark-Latina

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    aao.org/education/interview/selective-laser-trabeculoplasty

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aao.org

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 2 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    American Board of Ophthalmology

    1987
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org
  • Fellowship in Glaucoma

    Massachusetts Eye and Ear

    1986
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org
  • Residency in Ophthalmology

    Massachusetts Eye and Ear Infirmary / Harvard Medical School

    1985
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org
  • MD

    University of Connecticut School of Medicine

    1980
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org
  • BA Chemistry

    Tufts University (Summa Cum Laude, Phi Beta Kappa)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →specialtyeyeconsultants.com

Editorial & leadership roles

journal and society appointments
  • Fellow

    American Academy of Ophthalmology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Featured expert video

    "Mark Latina, M.D. Discusses Glaucoma Tube Shunt Technology", AAO 2012, OphthalmologyWeb

    2012
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophthalmologyweb.com
  • Podcast guest

    "Dr. Mark Latina and Dr. Gus Gazzard: SLT, LiGHT Trial, Glaucoma", The History of Eyecare podcast, episode 16

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thehistoryofeyecare.com
  • Educational contributor

    "Why Your Glaucoma Suspects Deserve Another Look: ERG and SLT", Diopsys resource

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →diopsys.com
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.